申请人:GLAXOSMITHKLINE SPA
                            
                            
                                公开号:WO2002043734A1
                            
                            
                                公开(公告)日:2002-06-06
                            
                            Certain compounds of formula (I) or a pharmaceutically acceptable salts or hydrate thereof wherein R1 is H or alkyl; R2 is aryl or cycloalkyl or heteroaryl; R3 is H or alkyl, optionally substituted by one or more fluorines; R4 is -NR8R9 or R12; r8 is H or methyl; R9 is H, alkyl, aryl, cycloalkyl or R10R11; or R8 and R9 together form a heterocyclic ring comprising 3-8 ringe members, which heterocyclic ring is optionally unsubstituted or is substituted one or more times by R11; R10 is alkyl, aryl or cycloalkyl; R11 is carboxy or alkylcarboxy; R12 is R13 or OR13; R13 is H or alkyl or aryl, optionally substituted by one or more fluorines; R5 is branched or linear alkyl, cycloalkyl, cycloalkylalkyl, aryl, or a single or fused ring aromatic heterocyclic group; R6 represents H or up to three substituents independently selected from the list consisting of: alkyl, alkenyl, aryl, alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, alkoxycarbonyl, trifluoromethyl, acyloxy, amino or mono or di-alkylamino; R7 is H or halo; a is 1-6; and any of R2, R5, R9, and R10 may optionally be substituted one or more times by halo, hydroxy, amino, cyano, nitro, carboxy or oxo; a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.